

---

**Operations Office**

Telephone (507) 266-3853

---



**Date:** July 7, 2009

**To:** NCCTG Primary CRAs, Primary PIs

**From:** Linda S. Long  
Research Protocol Specialist III

**Re:** **N0745, Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma**

Addendum 1 for this study was recently distributed and was effective July 3, 2009. On page 13 of both Appendix IA and Appendix IB (under “Things to Think About), the reference to “blood” was incorrectly deleted from the consent forms. The paragraphs should read as follows and the consent forms will be corrected in the next addendum.

The choice to let us keep the left over **blood and/or** tissue sample(s) for future research is up to you. No matter what you decide to do, it will not affect your care.

If you decide now that your **blood and/or** tissue sample(s) can be kept for **future** research, you can change your mind at any time. You or your physician will need to write to: Quality Assurance Specialist, N0745, North Central Cancer Treatment Group (NCCTG) Operations Office, 200 First Street SW, Rochester, MN 55905. Then any **blood and/or** tissue sample(s) that remain will no longer be used for **future** research.

If you have any questions concerning this communication, please contact me at 507/266-3853.